Intellia Therapeutics, Inc. (NASDAQ:NTLA) had its price target increased by research analysts at Credit Suisse Group from $24.00 to $28.00 in a research note issued on Friday. The firm presently has an “outperform” rating on the stock. Credit Suisse Group’s target price points to a potential upside of 27.62% from the company’s previous close.
A number of other brokerages have also commented on NTLA. Jefferies Group LLC set a $42.00 price objective on Intellia Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, October 31st. Zacks Investment Research upgraded Intellia Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, October 4th. Leerink Swann lifted their price objective on Intellia Therapeutics from $29.00 to $37.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 31st. They noted that the move was a valuation call. Wedbush reiterated an “ourperform” rating and issued a $25.00 price objective (down from $29.00) on shares of Intellia Therapeutics in a research report on Wednesday, September 27th. Finally, ValuEngine upgraded Intellia Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 22nd. Five equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Intellia Therapeutics currently has an average rating of “Hold” and a consensus target price of $30.17.
Shares of Intellia Therapeutics (NASDAQ:NTLA) traded up $0.94 during mid-day trading on Friday, reaching $21.94. The company had a trading volume of 1,761,134 shares, compared to its average volume of 745,927.
Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Tuesday, October 31st. The company reported ($0.44) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.50) by $0.06. The firm had revenue of $7.30 million during the quarter, compared to analyst estimates of $5.83 million. Intellia Therapeutics had a negative return on equity of 28.01% and a negative net margin of 215.92%. The company’s revenue was up 49.0% on a year-over-year basis. During the same period last year, the company earned ($0.22) earnings per share. equities research analysts expect that Intellia Therapeutics will post -1.68 EPS for the current fiscal year.
Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its position in shares of Intellia Therapeutics by 10.2% during the 2nd quarter. Vanguard Group Inc. now owns 997,288 shares of the company’s stock worth $15,957,000 after buying an additional 92,580 shares during the period. ARK Investment Management LLC grew its position in shares of Intellia Therapeutics by 118.9% during the 2nd quarter. ARK Investment Management LLC now owns 174,810 shares of the company’s stock worth $2,797,000 after buying an additional 94,960 shares during the period. State Street Corp grew its position in shares of Intellia Therapeutics by 52.0% during the 2nd quarter. State Street Corp now owns 164,798 shares of the company’s stock worth $2,638,000 after buying an additional 56,363 shares during the period. Geode Capital Management LLC grew its position in shares of Intellia Therapeutics by 6.0% during the 1st quarter. Geode Capital Management LLC now owns 76,095 shares of the company’s stock worth $1,072,000 after buying an additional 4,291 shares during the period. Finally, OxFORD Asset Management LLP acquired a new position in shares of Intellia Therapeutics during the 2nd quarter worth about $1,132,000. Institutional investors own 47.77% of the company’s stock.
Intellia Therapeutics Company Profile
Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.
What are top analysts saying about Intellia Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Intellia Therapeutics Inc. and related companies.